Marengo Therapeutics Announces Publication Describing STAR0602, a Novel, TCR-Targeting Cancer Immunotherapy, in Science Translational Medicine

Marengo Therapeutics, Inc. today announced that its lead program, STAR0602, is the subject of an article published in the latest edition of Science Translational Medicine.